Flexion Therapeutics, Inc. (NASDAQ:FLXN) has received an average rating of “Buy” from the eleven analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $32.25.

A number of research analysts have recently weighed in on the company. BMO Capital Markets restated a “buy” rating on shares of Flexion Therapeutics in a report on Friday. Needham & Company LLC restated a “buy” rating and issued a $36.00 target price (up previously from $34.00) on shares of Flexion Therapeutics in a report on Thursday, August 10th. Royal Bank Of Canada restated an “outperform” rating and issued a $44.00 target price on shares of Flexion Therapeutics in a report on Thursday, August 10th. Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Finally, Janney Montgomery Scott restated a “buy” rating and issued a $35.00 target price (up previously from $30.00) on shares of Flexion Therapeutics in a report on Wednesday, July 12th.

In other Flexion Therapeutics news, insider Michael D. Clayman purchased 5,000 shares of the firm’s stock in a transaction that occurred on Monday, June 5th. The stock was bought at an average cost of $17.23 per share, with a total value of $86,150.00. Following the completion of the transaction, the insider now owns 20,146 shares of the company’s stock, valued at approximately $347,115.58. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark Stejbach purchased 1,580 shares of the firm’s stock in a transaction that occurred on Friday, June 16th. The shares were acquired at an average cost of $17.02 per share, with a total value of $26,891.60. The disclosure for this purchase can be found here. Company insiders own 15.98% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. Fiduciary Trust Co. acquired a new stake in shares of Flexion Therapeutics during the second quarter worth approximately $101,000. IFP Advisors Inc increased its stake in shares of Flexion Therapeutics by 24.5% in the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 1,000 shares during the last quarter. Advisor Group Inc. increased its stake in shares of Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after buying an additional 3,500 shares during the last quarter. Monarch Partners Asset Management LLC acquired a new stake in shares of Flexion Therapeutics during the first quarter worth approximately $279,000. Finally, Asset Management One Co. Ltd. acquired a new stake in shares of Flexion Therapeutics during the first quarter worth approximately $319,000. 78.01% of the stock is owned by institutional investors.

WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/15/flexion-therapeutics-inc-flxn-receives-consensus-recommendation-of-buy-from-brokerages-2.html.

Flexion Therapeutics (NASDAQ FLXN) traded down 1.59% on Tuesday, hitting $22.33. The company’s stock had a trading volume of 186,058 shares. The firm has a 50 day moving average of $22.63 and a 200-day moving average of $21.33. The stock’s market cap is $712.44 million. Flexion Therapeutics has a 12 month low of $15.44 and a 12 month high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by $0.11. On average, analysts expect that Flexion Therapeutics will post ($3.68) earnings per share for the current fiscal year.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.